Africa: Gilead Under Fire for Not Selling HIV Drug Lenacapavir to MSF

Africa: Gilead Under Fire for Not Selling HIV Drug Lenacapavir to MSF

Pharmaceutical company Gilead Sciences has come under mounting pressure after refusing to sell its breakthrough HIV prevention drug, lenacapavir, directly to Médecins Sans Frontières (MSF), despite repeated requests. In an open letter, the group renewed its repeated requests to California-based Gilead to sell the drug, saying the company is blocking lenacapavir’s rollout. MSF said it had sought to purchase…

Read More
Africa: Global Fund Secures Access to Breakthrough HIV Prevention Drug Lenacapavir for Low – and Middle-Income Countries

Africa: Global Fund Secures Access to Breakthrough HIV Prevention Drug Lenacapavir for Low – and Middle-Income Countries

Geneva — A pivotal moment in the fight to end AIDS — ensuring lifesaving innovation reaches those who need it most, wherever they live The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) today announced it has signed an access agreement with Gilead Sciences to procure lenacapavir, a long-acting injectable for HIV…

Read More